Molecular Comparison and Safety Profiles of Fezolinetant and Elinzanetant
Panelists discuss why elinzanetant is likely to be associated with a lower risk of liver injury due to its distinct molecular structure compared to fezolinetant, and compare the adverse event profiles of the 2 drugs, highlighting that elinzanetant is more commonly associated with headache and fatigue while fezolinetant is linked to abdominal pain, diarrhea, insomnia, and back pain.
- Why will elinzanetant likely be associated with a lower risk of liver injury?
(ie, molecular structure is very different from fezolinetant; liver toxicity is generally related to certain structural elements and not its receptor binding properties)
- How do the adverse event profiles differ among fezolinetant and elinzanetant?
Notes: In phase 3 clinical trials, headache and fatigue were the most common adverse events with elinzanetant. In a phase 3, 52-week safety study, The most common adverse events with fezolinetant were abdominal pain, diarrhea, insomnia, back pain, and hot flashes.
